Benitec Biopharma Inc reports results for the quarter ended in December - Earnings Summary

Benitec Biopharma

13/02/2023 14:30

* Benitec Biopharma Inc  BNTC.OQ  reported a quarterly
adjusted
loss of 20 cents​​ per share for the quarter ended in December.
The lone analyst forecast for the quarter was for a loss of 11
cents per share.
    * Revenue fell 44% to $14.00 thousand from a year ago;
analysts
expected zero. 
    * Benitec Biopharma Inc's reported EPS for the quarter was a
loss
of 20 cents​.
    * The mean earnings estimate of analysts had risen by
about 24.1%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Benitec Biopharma Inc shares had risen by 58.8% this
quarter.
    * The company reported a quarterly loss of $5.41 million.
    * Wall Street's median 12-month price target for Benitec
Biopharma
Inc is $4.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data February
13 at 02:30 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.11          -0.20          Missed
 Sep. 30 2022      -0.18          -0.47          Missed
 Jun. 30 2022      -0.28          -0.62          Missed
 Mar. 31 2022      -0.44          -0.40          Beat